(Q57757597)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Emre Demirci

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Meltem Ocak

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Clemens Decristoforo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Ahmet Araman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Yıldız Ozsoy

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Ilhami Uslu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Bedii Kanmaz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

20 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

number of pages

7

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1271-1277

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-012-2123-y

29 January 2020

exact match

0 references

cites work

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

A fully automated synthesis for the preparation of 68Ga-labelled peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

'Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2123-Y

Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions

21 January 2018

1 reference

12 December 2020

Distribution pattern of 68Ga-DOTATATE in disease-free patients.

1 reference

12 December 2020

Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography

1 reference

12 December 2020

Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors

1 reference

12 December 2020

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

12 December 2020

Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility

1 reference

12 December 2020

10.1007/S00259-012-2123-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22526963%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference